VEGF/VEGFR‐2 have unique roles in the mediation and promotion of intraplaque angiogenesis.[19] Ramucirumab (Ram) is an FDA‐approved monoclonal antibody that binds to VEGFR‐2 to inactivate VEGF‐mediated downstream signaling pathways, leading to the inhibition of tumor neovascularization.[20] The developed PFP–HMME@PLGA/MnFe2O4–ramucirumab nanoplatform could actively target the mitochondria of rabbit aortic endothelial cells (RAECs), increasing nanoparticle accumulation in plaque neovessels. The gene discussed is KDR; the disease is neoplasm.